Navigation Links
Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis

EVRY, France, June 25, 2007 /PRNewswire/ -- Novagali Pharma, an emerging pharmaceutical company specialized in ophthalmology presents positive results of its pivotal phase III clinical trial positive results from the Phase III clinical study of Vekacia(R) in children suffering from Vernal Keratoconjunctivitis (VKC) at the XIV Afro-Asian Congress of ophthalmology (AACO) held from June 20 to 25 2007 in Marrakech (Morocco).

VKC is a severe form of chronic allergic conjunctivitis characterized by ocular discomfort, pain, itching and intense photophobia, which severely debilitates the patients. This rare disease affects mostly children and young adults living in warm climates worldwide. In this orphan disease, it was shown that both symptoms and signs of disease improved in patients receiving Vekacia(R). Furthermore, the tolerability of Vekacia(R) was excellent.

The study was designed as a clinical phase II/III, multicenter, randomized parallel group, double masked, dose ranging, controlled study divided in two treatment periods: (I) a four-week prospective, randomized, multicenter, double-masked, three parallel-group, vehicle-controlled treatment period; and (II) a three-month prospective, multicenter, double-masked treatment period.

The primary objective of Vekacia(R) phase III study was to assess the efficacy of Vekacia(R) 0.05 % and Vekacia(R) 0.1%, administered four times daily, versus a vehicle after a four-week treatment period for patients with VKC. The secondary objectives were to compare the safety and ocular tolerance (objective and subjective) and the long-term safety after four months.

One hundred and eighteen patients (mean age: 8.8) with active bilateral VKC (acute or chronic) were enrolled in the study at over 21 sites in Europe and Mediterranean countries from May 2006 to October 2006. Most patients were suffering from perennial VKC (90 patients, 76.3%) and were presented
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Novagali Pharma Announces Positive Vekacia Clinical Results From Pivotal Phase III Trial in Vernal Keratoconjunctivitis
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:8/20/2014)... Calif. , Aug. 20, 2014 The National ... Fernando Davila has been successfully treated for a ... by Dr, Anibal R. Gauto , Medical Director of ... at Eisenhower Medical Center in Rancho Mirage, California ... treatment pioneered by Dr. John Crew at Seton ...
(Date:8/20/2014)... , Aug. 20, 2014 Research and ... Report of Pralmorelin" report to their offering. ... providing comprehensive data on Pralmorelin globally and regionally ( ... North America , Latin America ... Pralmorelin This report focuses on three primary areas; ...
(Date:8/20/2014)... DUBLIN , Aug. 20, 2014 ... addition of the "Global Advanced Wound Care ... Geography) - Size, Share, Global Trends, Company Profiles, ... Forecast, 2013 - 2020" report to their ... "Global advanced wound care and closure market (types, ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
... 2011 3-V Biosciences, Inc. announced today Stephen R. Brady ... (Logo:   http://photos.prnewswire.com/prnh/20100513/LA04336LOGO ) "Steve,s contributions have been ... at 3-V," said Merdad V. Parsey, MD, PhD, 3-V,s Chief ... we continue to build the 3-V team and advance the ...
... 2011 Awarepoint Corporation today announced it conducted its ... and User Group , Viewpoint | 2011, January 23-25, ... http://photos.prnewswire.com/prnh/20100127/LA44915LOGO ) At this exclusive Awarepoint event, ... with other hospitals to share information and use cases ...
Cached Medicine Technology:3-V Biosciences Promotes Stephen R. Brady to Chief Business Officer 2Awarepoint Announces First Annual RTLS Customer Conference and User Group Results and Highlights 2Awarepoint Announces First Annual RTLS Customer Conference and User Group Results and Highlights 3Awarepoint Announces First Annual RTLS Customer Conference and User Group Results and Highlights 4
(Date:8/20/2014)... 20, 2014 A common approach to treating kidney ... not improve survival chances for people who suddenly developed ... the University of Pittsburgh School of Medicine. , Their ... , suggest acute hemodialysis, an aggressive method that is ... not provide a definitive benefit to the patient. , ...
(Date:8/20/2014)... (August 20, 2014) Research from Columbia University Medical ... in stomach cancer growth and that blocking nerve signals ... treatment for the disease. The study was conducted by ... with Duan Chen, MD, PhD, in Norway and is ... . , "Scientists have long observed that human and ...
(Date:8/20/2014)... 20, 2014 The non-small cell lung ... in the offing across the top 8 developed nations, ... to around USD 8 billion by 2020-end, posting a ... is projected to be driven by innovative therapies entering ... lacking efficient treatment, unlike the non-squamous segment. Thus, patients ...
(Date:8/20/2014)... Rosa, CA (PRWEB) August 20, 2014 The ... the 12 per diode panel band perfect spectrum that encompasses ... are most likely to use during photosynthesis. A key ... bands is that they almost exclusively reside between 440-480 on ... on the red side of the spectrum. The KIND LED ...
(Date:8/20/2014)... MI (PRWEB) August 20, 2014 In its ... drug and alcohol treatment program that gets clients off to ... recovery they can believe in, is highlighting an important and ... be heeded by everyone who wants to understand the insidious ... are of the belief that drug abuse targets a certain ...
Breaking Medicine News(10 mins):Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3
... Oct. 20 Strong new pledges of,commitment ... donors, government,officials, corporations, foundations and non-governmental organizations,today ... Deliver conference, which,sought to mobilize political will ... worldwide. More than 1,800 participants from ...
... YORK, Oct. 20 EmPower Research, LLC, a ... Consulting, launched its,first-ever study on the Indian Contract ... titled ,Indian Contract Research Industry, (CRO-nicles),captures the industry,s ... to the top line industry executives first hand. ...
... Following is a statement,by Linda A. Suydam, D.P.A., ... the recommendations issued today by the U.S.,Food and ... Committee. At a meeting this week, the joint ... medicines in children., "For decades, parents and ...
... Court, WILMINGTON, Del., Oct. 19 The following,statement ... W.Va., zinc,smelter class action lawsuit. The statement is to ... "We are extremely disappointed by the outcome of the ... unfairly punished for doing,the right thing for this property ...
... Mass., Oct. 19 LeMaitre Vascular,Inc. (Nasdaq: ... and implants for the treatment of peripheral vascular ... Annual Healthcare Conference on,Tuesday, November 6, 2007, in ... George W. LeMaitre, Chairman and Chief Executive Officer, ...
... the less the idea bothered her , , FRIDAY, Oct. ... the idea of childlessness than men, new research shows, ... how each gender views the pressures of parenthood. , ... and parenthood mean different things," said study author Tanya ...
Cached Medicine News:Health News:Women Deliver Conference Launches New Commitments 2Health News:EmPower Research Launches Indian CRO Industry Report 2Health News:Statement from the Consumer Healthcare Products Association on Today's Joint FDA Advisory Committee Recommendations Regarding Pediatric Over-the-Counter Cough and Cold Medicines 2Health News:DuPont Responds to Spelter, W.Va., Lawsuit Decision 2Health News:Childlessness Bothers Men More Than Women 2Health News:Childlessness Bothers Men More Than Women 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: